Patents by Inventor Nicole Suciu-Foca
Nicole Suciu-Foca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10765742Abstract: It has now been discovered that activated lymphocyte cell adhesion molecule (ALCAM)—also known as CD166—is the ligand of the innate immune receptor ILT3 that is expressed by DC and monocytes. It has been further discovered that the specific binding of ILT3 to its ligand CD166 on the surface of CD166-expressing cancer cells, arrested cancer cell growth and initiated apoptosis. Therefore, certain embodiments relate to methods and compositions for treating CD166-expressing cancers by administering ILT3Fc, full-length ILT3 or any CD166 ligand-binding fragment thereof.Type: GrantFiled: July 18, 2016Date of Patent: September 8, 2020Assignee: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, George Vlad, Zheng Xu
-
Patent number: 10670603Abstract: The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.Type: GrantFiled: May 31, 2017Date of Patent: June 2, 2020Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Nicole Suciu-Foca, George Vlad, Chih-Chao Chang, Zhuoru Liu, Adriana Ioana Colovai
-
Publication number: 20180207269Abstract: It has now been discovered that activated lymphocyte cell adhesion molecule (ALCAM)-also known as CD166-is the ligand of the innate immune receptor ILT3 that is expressed by DC and monocytes. It has been further discovered that the specific binding of ILT3 to its ligand CD166 on the surface of CD166-expressing cancer cells, arrested cancer cell growth and initiated apoptosis. Therefore, certain embodiments relate to methods and compositions for treating CD166-expressing cancers by administering ILT3Fc, full-length ILT3 or any CD166 ligand-binding fragment thereof.Type: ApplicationFiled: July 18, 2016Publication date: July 26, 2018Applicant: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, George Vlad, Zheng Xu
-
Patent number: 9822161Abstract: This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.Type: GrantFiled: June 8, 2015Date of Patent: November 21, 2017Assignee: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, George Vlad, Raffaello Cortesini
-
Publication number: 20170327591Abstract: The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.Type: ApplicationFiled: May 31, 2017Publication date: November 16, 2017Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Nicole Suciu-Foca, George Vlad, Chih-Chao Chang, Zhuoru Liu, Adriana Ioana Colovai
-
Patent number: 9696312Abstract: The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.Type: GrantFiled: September 4, 2012Date of Patent: July 4, 2017Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Nicole Suciu-Foca, George Vlad, Chih-Chao Chang, Zhuoru Liu, Adriana Ioana Colovai
-
Publication number: 20160152682Abstract: This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.Type: ApplicationFiled: June 8, 2015Publication date: June 2, 2016Applicant: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, George Vlad, Raffaello Cortesini
-
Patent number: 9150635Abstract: This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.Type: GrantFiled: May 24, 2012Date of Patent: October 6, 2015Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Nicole Suciu-Foca, Luigi Scotto, Seunghee Kim-Schulze, George Vlad, Raffaello Cortesini
-
Patent number: 9078858Abstract: This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.Type: GrantFiled: September 18, 2012Date of Patent: July 14, 2015Assignee: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, George Vlad, Raffaello Cortesini
-
Publication number: 20150110714Abstract: The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.Type: ApplicationFiled: September 4, 2012Publication date: April 23, 2015Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Nicole Suciu-Foca, George Vlad, Chih-Chao Chang, Zhuoru Liu, Adriana Ioana Colovai
-
Publication number: 20130156763Abstract: This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.Type: ApplicationFiled: September 18, 2012Publication date: June 20, 2013Applicant: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, George Vlad, Raffaello Cortesini
-
Publication number: 20120321623Abstract: This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.Type: ApplicationFiled: May 24, 2012Publication date: December 20, 2012Applicant: The Trustees Of Columbia University In The City Of New YorkInventors: Nicole Suciu-Foca, Luigi Scotto, Seunghee Kim-Schulze, George Vlad, Raffaello Cortesini
-
Patent number: 8299016Abstract: This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.Type: GrantFiled: April 7, 2009Date of Patent: October 30, 2012Assignee: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, George Vlad, Raffaello Cortesini
-
Patent number: 8207110Abstract: This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.Type: GrantFiled: September 1, 2005Date of Patent: June 26, 2012Assignee: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, Luigi Scotto, Seunghee Kim-Schulze, George Vlad, Raffaello Cortesini
-
Publication number: 20090280109Abstract: This invention provides compositions which comprise at least two of a CD4+CD25+ cell, IL-10, a CD8+CD28? cell and a vitamin D3 analog. This invention also provides methods for generating a tolerogenic antigen-presenting cell, and increasing the expression of ILT3 and/or ILT4 by an antigen-presenting cell. This invention further provides methods for inhibiting the onset of or treating the rejection of an antigenic substance and inhibiting the onset of or treating an autoimmune disease in a subject. This invention further provides methods for treating and preventing AIDS, cancer, and Hepatitis C-related disorders, and for identifying agents useful for such purposes. Finally, this invention provides related compositions and kits.Type: ApplicationFiled: February 22, 2008Publication date: November 12, 2009Applicant: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, Zhuoru Liu, Chih-Chao Chang, Raffaello Cortesini
-
Publication number: 20090274685Abstract: This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.Type: ApplicationFiled: April 7, 2009Publication date: November 5, 2009Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: NICOLE SUCIU-FOCA, GEORGE VLAD, RAFFAELLO CORTESINI
-
Publication number: 20090202544Abstract: This invention provides a method of treating a subject afflicted with a disease, comprising withdrawing blood from the subject, treating the withdrawn blood so as to remove sILT3 from the blood, and returning the treated blood to the subject, thereby treating the subject afflicted with the disease. This invention also provides the above method, further comprising administering an anti-ILT3 antibody to the subject. The invention also provides a method of treating a subject afflicted with a disease, comprising administering to the subject an anti-ILT3 antibody, thereby treating the subject. In one embodiment, the disease is chronic viral disease. In another embodiment, the disease is cancer.Type: ApplicationFiled: February 2, 2007Publication date: August 13, 2009Applicant: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, George Vlad, Raffaello Cortesini
-
Publication number: 20080311073Abstract: This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.Type: ApplicationFiled: September 1, 2005Publication date: December 18, 2008Inventors: Nicole Suciu-Foca, Luigi Scotto, Seunghee Kim-Schulze, George Vlad, Raffaello Cortesini
-
Patent number: 7144728Abstract: This invention also provides a method of generating antigen specific human suppressor CD8+CD28? T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28? T cells. Methods of tent for reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28? T cells so produced are also provided, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.Type: GrantFiled: June 15, 2000Date of Patent: December 5, 2006Assignee: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, Raffaello Cortesini, Zhuoru Liu, Chih-Chao Chang
-
Publication number: 20050250161Abstract: This invention provides a method of generating antigen specific allospecific human-suppressor CD8+CD28? T cells. This invention also provides a method of generating xenospecific human suppressor CD8+CD28? T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28? T cells. Methods of treatment for, reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28? T cells so produced are also provides, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.Type: ApplicationFiled: July 2, 2004Publication date: November 10, 2005Applicant: The Trustees of Columbia UniversityInventors: Nicole Suciu-Foca, Raffaello Cortesini, Zhuoru Liu, Chih-Chao Chang